FDMT
4D Molecular Therapeutics Inc
$
10.510
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
11.095
Open
10.5823
VWAP
10.72
Vol
279.04K
Mkt Cap
1.08B
Low
10.500
Amount
2.99M
EV/EBITDA(TTM)
--
Total Shares
51.70M
EV
-129.19M
EV/OCF(TTM)
--
P/S(TTM)
10.02K
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
1.16M
+116150%
-0.882
-2.01%
662.50K
+21983.33%
-0.944
+19.51%
662.50K
+13150%
-0.697
+10.67%
Estimates Revision
The market is revising No Change the revenue expectations for 4D Molecular Therapeutics, Inc. (FDMT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 57.57%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+57.57%
In Past 3 Month
6 Analyst Rating
Wall Street analysts forecast FDMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FDMT is 29.40 USD with a low forecast of 17.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
1 Sell
Moderate Buy
Current: 10.510
Low
17.00
Averages
29.40
High
38.00
Current: 10.510
Low
17.00
Averages
29.40
High
38.00
RBC Capital
Lisa Walter
Outperform
maintain
$26 -> $32
2025-11-11
New
Reason
RBC Capital
Lisa Walter
Price Target
$26 -> $32
2025-11-11
New
maintain
Outperform
Reason
RBC Capital analyst Lisa Walter raised the firm's price target on 4D Molecular to $32 from $26 and keeps an Outperform rating on the shares after its Q3 results. The company's current cash position of $372M plus additional funds from the recent APAC deal with Otsuka and capital raise should extend the runway by 6 months into the second half of FY28 and fund both wAMD and DME pivotals, the analyst tells investors in a research note, adding that the recent funding "adds some cushion to the runway".
Barclays
Gena Wang
Overweight
downgrade
$38 -> $33
2025-11-11
New
Reason
Barclays
Gena Wang
Price Target
$38 -> $33
2025-11-11
New
downgrade
Overweight
Reason
Barclays analyst Gena Wang lowered the firm's price target on 4D Molecular to $33 from $38 and keeps an Overweight rating on the shares. The firm views the company's Q3 update as "largely incremental." The Otsuka deal and equity offering extend 4D's cash runway to the second half of 2028, the analyst tells investors in a research note.
Morgan Stanley
Judah Frommer
Underweight -> Equal Weight
upgrade
2025-11-06
Reason
Morgan Stanley
Judah Frommer
Price Target
2025-11-06
upgrade
Underweight -> Equal Weight
Reason
Morgan Stanley analyst Judah Frommer upgraded 4D Molecular to Equal Weight from Underweight. The firm is also raising its price target view on the stock to a range of $7-$16 from the prior range of $3-$7. Morgan Stanley notes that class safety concerns among physicians and commercial dynamics have driven its view of retinal disease gene therapy to date. The firm notes however that its new rating is based on the continued positive data for 4D-150, recent biopharma interest, and growing enthusiasm for 4D-150 among key opinion leaders, the analyst tells investors in a research note.
Leerink
Outperform
to
NULL
downgrade
$17 -> $16
2025-08-11
Reason
Leerink
Price Target
$17 -> $16
2025-08-11
downgrade
Outperform
to
NULL
Reason
Leerink lowered the firm's price target on 4D Molecular to $16 from $17 and keeps an Outperform rating on the shares after the company announced Q2 results and completion of enrollment in the lower dose cohorts of the Phase 1 trial of 4D-710 in cystic fibrosis. The firm's revised target reflects updated R&D expense estimates for ongoing pivotal trials, the analyst noted.
Barclays
Gena Wang
Overweight
downgrade
$45 -> $38
2025-05-09
Reason
Barclays
Gena Wang
Price Target
$45 -> $38
2025-05-09
downgrade
Overweight
Reason
Barclays analyst Gena Wang lowered the firm's price target on 4D Molecular to $38 from $45 and keeps an Overweight rating on the shares. The firm updated the company's model post the Q1 report.
B of A Securities
Tazeen Ahmad
Strong Buy
Maintains
$42 → $40
2025-03-10
Reason
B of A Securities
Tazeen Ahmad
Price Target
$42 → $40
2025-03-10
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for 4D Molecular Therapeutics Inc (FDMT.O) is -1.36, compared to its 5-year average forward P/E of -5.95. For a more detailed relative valuation and DCF analysis to assess 4D Molecular Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-5.95
Current PE
-1.36
Overvalued PE
-2.23
Undervalued PE
-9.67
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.49
Current EV/EBITDA
0.94
Overvalued EV/EBITDA
0.95
Undervalued EV/EBITDA
-7.92
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
129.64
Current PS
55.54
Overvalued PS
272.38
Undervalued PS
-13.09
Financials
Annual
Quarterly
FY2025Q1
YoY :
-50.00%
14.00K
Total Revenue
FY2025Q1
YoY :
+40.60%
-53.62M
Operating Profit
FY2025Q1
YoY :
+48.06%
-47.97M
Net Income after Tax
FY2025Q1
YoY :
+30.30%
-0.86
EPS - Diluted
FY2025Q1
YoY :
+62.39%
-48.39M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
+175597.31%
-682.44K
FCF Margin - %
FY2025Q1
YoY :
+196.11%
-342.66K
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 278.29% over the last month.
Sold
0-3
Months
92.1K
USD
4
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
2.5M
Volume
3
0-12
Months
10.3M
Volume
5
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
2
2.3M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 278.29% over the last month.
Sold
0-3
Months
92.1K
USD
4
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
FDMT News & Events
Events Timeline
2025-11-10 (ET)
2025-11-10
08:05:06
4D Molecular anticipates funding to last through the second half of 2028.
2025-11-10
08:04:25
4D Molecular Announces Q3 Earnings Per Share of $1.01, Exceeding Consensus Estimate of 98 Cents
2025-11-06 (ET)
2025-11-06
07:45:34
4D Molecular's 4D-150 Demonstrates Effectiveness in Phase 1/2 Trial for Wet AMD
Sign Up For More Events
Sign Up For More Events
News
8.5
10-24ReutersEli Lilly invests in eye care by acquiring gene therapy company Adverum
5.0
09-12Newsfilter4DMT Unveils New Employment Incentive Grants
9.0
09-11NASDAQ.COMSNY's Gene Therapy for Eye Disease Receives FDA Fast Track Designation
Sign Up For More News
People Also Watch
APPS
Digital Turbine Inc
5.180
USD
-8.32%
LFMD
LifeMD Inc
4.720
USD
-6.90%
ESCA
Escalade Inc
12.790
USD
+0.95%
JRVR
James River Group Holdings Ltd
5.620
USD
0.00%
ACB
Aurora Cannabis Inc
4.440
USD
-1.99%
CIO
City Office REIT Inc
6.920
USD
-0.14%
SJT
San Juan Basin Royalty Trust
6.310
USD
+0.96%
SOPH
SOPHiA GENETICS SA
4.380
USD
+1.39%
AEYE
AudioEye Inc
11.910
USD
-5.63%
UTMD
Utah Medical Products Inc
56.250
USD
+0.09%
FAQ
What is 4D Molecular Therapeutics Inc (FDMT) stock price today?
The current price of FDMT is 10.51 USD — it has decreased -4.19 % in the last trading day.
What is 4D Molecular Therapeutics Inc (FDMT)'s business?
What is the price predicton of FDMT Stock?
What is 4D Molecular Therapeutics Inc (FDMT)'s revenue for the last quarter?
What is 4D Molecular Therapeutics Inc (FDMT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for 4D Molecular Therapeutics Inc (FDMT)'s fundamentals?
How many employees does 4D Molecular Therapeutics Inc (FDMT). have?